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Abstract
 Magnesium sulfate is used as a tocolytic, but clinical efficacy has been seriously questioned. 
Our objective was to use controlled ex vivo conditions and known pregnancy stages, to 
investigate how two key factors, hormones and gestation, affect Magnesium’s tocolytic 
ability. We hypothesized that these factors could underly the varying clinical findings around 
Magnesium’s efficacy. Myometrial strips were obtained from non-pregnant (n=10), mid-term 
(n=12) and term-pregnant (n=11) mouse uterus. The strips were mounted in organ baths 
superfused with oxygenated physiological saline at pH 7.4 and 37 °C.  The effect of different 
concentrations of MgSO4 (2 – 20mM) was examined on spontaneous and oxytocin-induced 
(0.5-1nM) contractions. Contractile properties (amplitude, frequency and area under the 
curve, AUC) were measured before and after application of Magnesium.  Magnesium sulfate 
had a dose-dependent inhibitory effect on both spontaneous and oxytocin-induced 
contractions but was less effective in the presence of oxytocin. In spontaneous contractions, 
Magnesium was more potent as gestation progressed (P<0.0001).  In the presence of oxytocin 
however, there were no significant gestational differences in its effects on contraction.  The 
rapid onset and reversal of Magnesium’s effects suggest an extracellular action on Calcium 
entry. Taken together we conclude that Magnesium’s actions are influenced by both 
gestational state and hormones, such that, at least in mice, it is least effective in early 
gestation with oxytocin present, and most effective at term in the absence of oxytocin.  That 
Magnesium is least effective preterm and oxytocin decreases its effectiveness throughout 
gestation, may explain its disappointing clinical effects as a tocolytic.
Keywords: tocolysis, contraction, uterus, preterm birth. Oxytocin.
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Introduction
The high incidence of preterm birth, >10% of births worldwide, remains unchanged despite 
much research effort and advancement in understanding uterine physiology 1. It is the single 
largest cause of mortality and morbidity in newborns. Several tocolytics including oxytocin-
receptor antagonists e.g. atosiban, prostaglandin synthesis inhibitors e.g. indomethacin, 
calcium channel blockers e.g. nifedipine, beta-2 agonists e.g. ritodrine, and magnesium 
sulfate (MgSO4) have been developed to help prolong pregnancy, by reducing or slowing 
uterine contractions when preterm labour threatens. Unfortunately, it remains the case that 
none are ideal in terms of either efficacy or side effects, and perhaps not surprisingly there is 
little international consensus on which tocolytic to use to help manage spontaneous preterm 
labour. 
 Magnesium sulfate was described as a tocolytic in 1959 2 and shortly after became the 
preferred drug in treating preterm labour. More recently however, studies including 
Cochrane systemic reviews3 4 have suggested that MgSO4 is ineffective in the treatment of 
preterm labour. For example Crowther et al., (2014) concluded that it was no better than 
placebo for the primary outcome of giving birth within 48 hours of trial entry, and nor was 
there any significant difference for the primary outcome of serious infant morbidity 3. In 
contrast, MgSO4 has been shown to be the drug of choice in treatment of seizures in 
eclampsia5 and prevention of preeclampsia in hypertensive pregnant women6. Additionally, 
MgSO4 has been shown to have neuroprotective effects in preterm fetuses at delivery, 
reducing the risk of death, cerebral palsy, and gross motor dysfunction7. 
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In contrast to clinical findings, in vitro studies have consistently found that Magnesium has a 
relaxant effect on smooth muscles including airway 8 and vascular 9.  Studies in myometrial 
smooth muscle show it to be a relaxant in several species10-13; it significantly inhibits 
contractions in a concentration-dependent manner12,14. 
In smooth muscles, Magnesium inhibits contractility via multiple mechanisms 
including effects on extracellular calcium entry, intracellular calcium release and calcium 
oscillations 15. It primarily acts by competing with Ca2+  at the L-type, voltage-operated 
Calcium channel (VOCC), resulting in a decrease in intracellular calcium concentration 15   The 
channel is comprised of four subunits, of which α-1 is the pore forming, voltage sensitive and 
conducting component, and the others modulate its activity. Progression of gestation has 
been linked to an increase in α-1 expression, and VOCC activity increases close to term 16-18. 
These findings suggest that Calcium channel density and expression increases with gestation.  
As Magnesium’s main action is at the Calcium channel, the question arises: could these 
changes in Calcium channel density and expression alter the effectiveness of Magnesium at 
different gestational ages? 
Of the hormonal changes around labour, oxytocin has a pivotal role 19. Oxytocin stimulates 
myometrial activity via a variety of mechanisms, including increasing Ca2+ entry into the 
myometrium via L-type channels and stimulating Calcium release from the sarcoplasmic 
reticulum (SR)20,21.  Oxytocin stimulation would therefore be expected to mitigate the actions 
of Magnesium.  Thus if women with threatened preterm labour had differing levels of 
oxytocin or differences in levels of expression of its receptor22, this may also alter 
responsiveness to Magnesium tocolysis in vivo. 
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It would be of benefit if the in vivo and in vitro findings concerning Magnesium’s effects on 
uterine contractility could be reconciled. This could then enable a stratification of which 
threatened spontaneous preterm labors may benefit from its use as a tocolytic. Our approach 
was to consider if there may be physiological factors which affect Magnesium’s efficacy in 
vivo.  Preterm births are defined as those before 37 completed weeks of gestation, and thus 
cover a very large gestational age range and much change in myometrial physiology and 
hormonal conditions23-26. These changes can be anticipated to also affect Magnesium‘s 
tocolytic ability.
While the effect of Magnesium in animal and human term-pregnant myometrium on 
spontaneous 12-14 and oxytocin induced contractions 12,14,15, has received some attention, the 
effect of Magnesium at different gestational stages has not been systematically investigated. 
In addition, neither has the influence of oxytocin on Magnesium’s action been studied 
throughout gestation. Furthermore, much can be learnt from mouse animal models, but we 
can find only one study where they have been used to look at Magnesium’s relaxant effect, 
and that was on day 14 of pregnancy in lipopolysaccharide (LPS)-treated animals 27.  
The aim of this study therefore was to investigate whether the relaxant effects of 
Magnesium are altered by gestational state and to test the hypothesis that the stimulation 
provided by oxytocin will significantly reduce the relaxant effects of Magnesium.
Methods
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Solutions 
All study solutions were prepared fresh at the start of each experiment by direct dissolving of 
MgSO4 or MgCl2 in buffered physiological saline solution (PSS) composed of (mM): NaCl 154, 
KCl 5.6, MgSO4 1.2, CaCl2 2, Glucose 8 and HEPES 10.2 28. Basal or control MgSO4 therefore 
was 1.2mM. Oxytocin was prepared in distilled water and added to the PSS to give a final 
concentration of 0.5nM (pregnant tissues) or 1nM (non-pregnant tissues). A 1nM 
concentration of oxytocin was used for non-pregnant tissues to ensure a similar stimulation 
to that seen in pregnant tissues was achieved. The concentration of water did not exceed 
0.01%. All chemicals were obtained from Sigma UK.
Tissue collection and preparation19 
Non-pregnant, 14- and 16- day (referred to as mid-pregnant) and 18 day (term) pregnant mice 
were humanely killed using CO2 anaesthesia and cervical dislocation, in accordance with UK 
Home Office regulations. All mice used were between 8-10 weeks old. The uterus was 
removed, cleaned of placentas and membranes (where applicable) and full-thickness 
(endometrium intact) myometrial strips (1 x 2 x 10 mm) were dissected along the longitudinal 
axis21. Using surgical thread, individual strips were mounted between a fixed support and a 
10g isometric force transducer (World Precision Instruments, UK) within a 5ml tissue bath 
(Linton Instruments, UK) under a resting tension of 5mN and were continuously superfused 
with oxygenated (95% O2, 5% CO2) PSS at pH 7.4, at a rate of 5mL/min and maintained at 
37oC to mimic physiological conditions29.
Experimental protocol
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For spontaneous contractions, strips were allowed to equilibrate for 45-60 minutes until 
regular, frequent and equal amplitude contractions were observed. For oxytocin-induced 
contractions, strips achieved regular spontaneous activity as above, ahead of addition of 
oxytocin which remained in the superfusate throughout. The uterine strips were then 
exposed to increasing concentrations of MgSO4 from 2 – 10 mM (spontaneous) and 2 – 12 
mM (oxytocin-induced) for 15 minutes or MgSO4 or MgCl2 (10mM and 20mM), either in the 
presence or absence of oxytocin. 
Analysis and statistics 
Myometrial contractions were continuously recorded via the force transducer connected to 
a data acquisition system equipped with Labtrax software (World Precision Instruments, 
UK)29. For each recording, the amplitude, frequency and force integral (area under the curve, 
(AUC) of contraction were measured, both during the control period (contractions occurring 
in the ten minutes immediately preceding the first application of Magnesium) and during the 
final ten minutes of each step in the concentration-response period.  Data were analysed 
using Origin Pro 2015 (Origin Lab Corporation, MA, USA) and are presented as percentage of 
control to reflect the effect of Magnesium, where the control period is taken as 100%. Values 
given are mean ± standard error of the mean (SEM) unless stated otherwise and were 
compared by ANOVA., n is the number of myometrial tissue strips, each one from a different 
animal, N.  
Concentration-response curves for AUC were fitted to the logistic equation with the use of 
non-linear regression.  The concentration at which MgSO4 caused a 50% reduction (IC50) in 
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overall contractile activity  (AUC) was calculated. LogIC50s were compared by the extra sum 
of squares F test or ANOVA followed by Bonferroni post-hoc analysis.
All statistical analysis was carried out using Graphpad Prism 5, significance was taken as 
P<0.05. Summary of analyses performed:
1) Effect of MgSO4  vs. MgCl2 - compared using t tests.
2) Tables 1 and 2- ANOVA with Bonferroni post hoc correction.
3) Comparison of LogIC50 values for Magnesium on spontaneous or oxytocin contractions 
between gestational groups – ANOVA with Bonferroni post hoc correction.
4) Comparison of LogIC50 values for effect of magnesium on spontaneous vs. oxytocin 
simulated contractions at each gestation -  Extra sum of squares F-test.
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Results
Control data and effects of Magnesium on late-pregnant mouse myometrium.
As there were little or no data concerning the actions of Magnesium on mouse myometrium, 
initial experiments were performed to, determine that Magnesium affected contractility, that 
the effects of MgSO4 were due to Magnesium and not the anion, and to obtain an indicative 
concentration for concentration-response curves. 
As shown in Figures 1A and 1B, stable, control contractions from pregnant mouse 
myometrium could be obtained for several hours without decrement in spontaneously active 
(A) and oxytocin-stimulated (B) tissues (typical of 9 preparations). Figure 1 also shows typical 
traces obtained using either 10 mM and 20 mM MgSO4, (1C) or, MgCl2 (1D), from three paired 
experiments (different animals), on oxytocin-stimulated pregnant myometrium. No 
significant differences were found between the effect of 10mM MgSO4 and MgCl2: amplitude: 
70 + 14% and 77 + 9%; AUC: 50 + 7 and 58 + 2%, respectively, nor were any significant 
differences found between MgSO4 or MgCl2 during spontaneous activity (data not shown). 
Based on these data, the remaining experiments were performed using MgSO4 as it is the 
sulfated form which is used clinically, and the effects of different concentrations and gestation 
were examined.
Effects of Magnesium on spontaneous contractions at different gestational states.
The effects of the application of increasing concentrations of MgSO4 in the superfusate 
bathing the spontaneously contracting myometrial strips were examined and compared at 
day 14, 16 and 18 of pregnancy, and non-pregnant. Concentration-dependent inhibitory 
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effects of Magnesium were found at each gestational state investigated as well as non-
pregnant tissues.  Representative isometric recordings are shown in Figure 2.  For all 
preparations, there was a decrease in frequency of contractions followed by a reduction in 
contraction amplitude.  The mean data for frequency, amplitude and AUC for spontaneous 
contractions for each group are given in Table 1. The data show that Magnesium reduces 
spontaneous activity of the myometrium in all tissue groups, with its effect becoming more 
marked (and significant) as term approaches: In non-pregnant and day 14-gestation tissues, 
contractions in the presence of 10mM MgSO4 still persisted, with the AUC being 40- and 18% 
of control respectively (Figure 2A-C).  In term-pregnant myometrium 10mM MgSO4 further 
and significantly reduced the AUC to negligible values (6%, Figure 2D).  The increased effects 
of Magnesium with gestation can also be appreciated from the fact that, in non-pregnant, day 
14 and 16 tissues, contractions were abolished in just 1/22 preparations (on day 16), whereas 
at term, Magnesium abolished contractions in over half the tissues (6/11 preparations).  In all 
preparations however, including those where contractions were abolished (e.g. Figure 2D), 
spontaneous contractions recovered to control values upon return to normal physiological 
saline (MgSO4 1.2mM).
Plotting AUC concentration-response curves and calculating the IC50 values for Magnesium 
confirmed the mean data findings. The order of potency for MgSO4 on spontaneous 
contractions was term-pregnant>mid-pregnant>non-pregnant, (Figure 2E).  The IC50 values 
fell from 7.06mM ± 0.32 (non-pregnant, n=10) to 4.75mM ± 0.21 (d 14, n=9) to 3.08mM ± 
0.16 (term, n=11, P<0.001). There was no significant difference between the IC50 values for 
MgSO4 at 14d and 16d gestation (4.75mM ± 0.21 and 5.50mM ± 0.26 respectively, P>0.05). 
Effects of Magnesium on oxytocin-induced contractions at different gestational stages.
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Having found significant effects of Magnesium on spontaneous contractility we next 
investigated whether these effects were altered when the tissues were stimulated with 
oxytocin. Using the same protocol as for spontaneous contractions, the data obtained in the 
presence of oxytocin also showed a concentration-dependent decrease in all parameters of 
contraction. This was evident in all tissue groups. Representative traces showing the effect of 
MgSO4 in the presence of oxytocin are given in Figures 3A-D and the mean data are given in 
Table 2.  
Unlike spontaneous activity, in the presence of oxytocin, the myometrium was still producing 
significant amounts of force at 10mM Magnesium in all preparations. In order therefore to 
accurately plot concentration-response curves, assist with curve fitting and better understand 
the response of the tissue, Magnesium was increased to 12 and 20 mM.  Typical responses to 
20mM Magnesium are shown in Figure 1C.  
As is clear in the example traces in Figure 3, for all pregnant tissues, a less potent inhibition 
with Magnesium was found in the presence of oxytocin compared to its application to 
spontaneous contractions, i.e. without oxytocin (Figure 2). Additionally, in pregnant tissues, 
concentration-response curves for Magnesium in the presence of oxytocin were also shifted 
to the right compared to spontaneous contractions (Figure 3E and 4B-D), resulting in 
significantly greater IC50 values with oxytocin stimulation. The greatest shift in IC50 values was 
seen for term-pregnant tissues from 3.08mM ± 0.16 in spontaneous conditions to 9.75mM ± 
0.21 with oxytocin (P<0.0001). A significant shift in IC50 values was also seen for day 14 
gestation tissues from 4.75mM ± 0.21 in spontaneous conditions to 10.25mM ± 0.24 in 
oxytocin (P<0.0001) and day 16 gestation tissues from 5.50mM ± 0.26 in spontaneous 
conditions to 9.35m ± 0.38 in oxytocin (P=0.0031). In contrast, in non-pregnant tissues, the 
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presence of oxytocin (even at 1nM) did not significantly alter the IC50 values for Magnesium: 
7.06mM ± 0.32 in spontaneous to 8.07mM ± 0.40 in the presence of oxytocin (Figure 4A, 
P=0.3236), hence in non-pregnant tissues, Magnesium is equipotent in the presence and 
absence of oxytocin.
Our data showed that, a consequence of oxytocin significantly increasing the IC50 values in all 
pregnant tissues, was that there were no longer any gestational differences between them, 
in the effects of Magnesium (Figure 4).  In other words, there was no significant differences 
in the inhibitory effect of Magnesium as pregnancy progressed, unlike what had been found 
above for spontaneous conditions. Instead, in the presence of oxytocin, the potency of MgSO4 
was reduced such that it was similar to its potency in non-pregnant tissues irrespective of 
pregnancy.
Discussion
Magnesium has been reported to suppress myometrial contractions and for this reason has 
been used over the last five decades in the treatment of preterm labour. Many clinical studies 
however, including Cochrane reviews 3, conclude or suggest that MgSO4 is ineffective at 
delaying labour. Thus, the clinical use of MgSO4 in the treatment of preterm labour is 
questioned30-32, highlighting the need for further studies. This study was conducted to better 
understand the effects of Magnesium on uterine contractility. It was designed to examine if 
physiological changes, namely gestational state and hormonal background, could influence 
myometrial responses to Magnesium.  In this way, a better understanding of the 
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disappointing clinical findings will be obtained and perhaps suggest a more stratified 
approach to its use as a tocolytic, to help prevent preterm labour. Magnesium’s effects as a 
tocolytic may synergise with its use and action to treat eclampsia. Our data provide fresh 
insights, as they show that preterm myometrium is much less sensitive to the relaxant effects 
of Magnesium than term myometrium, which could explain its lack of clinical efficacy. If 
oxytocin was present, its efficacy was further decreased, at all gestational stages. Thus, taken 
together we conclude that Magnesium’s actions are influenced by both gestational state and 
hormones, such that, at least in mice, it is least effective in early gestation with oxytocin 
present, and most effective at term in the absence of oxytocin.  
In vitro Mouse myometrium
We conducted our study on mouse myometrium so that we could obtain myometrial 
preparations at several stages of gestation as well as non-pregnant tissue. Myometrium from 
pregnant mouse has previously been reported to produce rhythmic spontaneous contractions 
in vitro for many hours21.  Consistent with this, we found all the uterine strips generated 
spontaneous contractions which were stable within a period of 45 -60 minutes, and remained 
regular without significant reduction in amplitude or frequency for many hours. This therefore 
allowed the effect of incremental concentrations of Magnesium to be examined and 
concentration-response curves to be fitted. There has been just one previous report of 
Magnesium's actions on mouse myometrium, in a lipopolysaccharide model of preterm 
birth27. These authors only studied mid-gestation (14 day) uterus and reported inhibition of 
spontaneous contractions with Magnesium; an effect which was decreased by 
lipopolysaccharide.  Our findings of an inhibitory effect on term-and non-pregnant 
myometrium are consistent with findings in other species10,12,14,15,33 including humans. Future 
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studies should attempt to obtain human biopsies at different stages of gestation to confirm 
these findings herein, although obtaining preterm biopsies is challenging.  In addition, to 
reflect the somewhat heightened state of contraction that may be associated with preterm 
labor compared to the non-laboring strips used here, a preterm labor mouse model, such as 
that induced by LPS or other agents, cshould be used to investigate the in vivo therapeutic 
effect of MgSO4.   
Magnesium’s mechanism of action in myometrium.
The effect of MgSO4 on contractions at different gestational stages was investigated and our 
data shows that regardless of gestational age or pregnancy status, it can reduce myometrial 
contractions. This inhibitory effect was reversible and the prompt recovery after washout 
suggests no ill effects of Magnesium on myometrium, even at high concentrations. The 
concentrations of MgSO4 used by us in vitro were empirically determined, and in the case of 
oxytocin-evoked contractions, going in to pharmacological rather than physiological 
concentrations, to enable maximal effects to be obtained. 
It is unlikely that intracellular Magnesium will have risen during the course of the 
experimental protocol,  due to the activity of  Na+ - Mg2+ exchangers and intracellular 
buffers34, as well as Magnesium's  slow penetrability through cell membranes 35. That the 
effects of Magnesium on the myometrium are relatively rapid and reversible, suggests that 
its main mechanism of action is likely to be extracellular. The rapid reversal of Magnesium’s 
effect is clinically useful, for example if delivery is by cesarean section, as it reduces the risk 
of postpartum haemorrhage 36. Magnesium use in preeclampsia has been associated with 
increased post-partum haemorrhage in some studies 37, but in another study, its use was not 
associated with additional blood loss 38. 
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The major mechanism of Magnesium’s action to relax uterine smooth muscle is, as with other 
excitable tissues, due to its cationic competition with Calcium 15.  In myometrium, 
contractions, whether spontaneous or agonist induced, are critically dependent upon Calcium 
entry through L-type Calcium channels39,40.  Thus when increased Magnesium competes with 
Calcium, entry of Calcium falls and hence contractions reduce and can even be abolished, as 
we and others have shown 13. The fall in intracellular Calcium will also lead to a fall in the 
Calcium content of the sarcoplasmic reticulum (SR)41. This reduced SR Calcium available when 
agonists such as oxytocin produce IP3, will reduce their ability, to increase myometrial 
contractility15. In this way, Magnesium will be expected to reduce the force of spontaneous 
and oxytocin-induced contractions. Fomin et al., (2006) showed that MgSO4 reduced 
spontaneous, oxytocin- and KCl-induced myometrial contractility and all were associated with 
a decrease in intracellular Calcium34. In addition, they found no shift in the force-Ca 
relationship in the myometrium. Together this provides strong evidence that Magnesium’s 
effects are predominantly extracellular and on Calcium entry. 
At all gestations and in non-pregnant tissue, our data show a significant reduction in force 
and frequency of contractions with addition of MgSO4. A reduction in force is most likely 
because of Magnesium’s antagonistic effect with Calcium at L-type calcium channels, as 
discussed above. Frequency of contractions is mainly dependent on excitability and 
membrane potential, hence a reduction in frequency suggests the pacemaker activity may 
also be affected by MgSO4 11. For example, should differences in the resting membrane 
potential of some pacemaker cells exist, it may make them more susceptible to the effects 
of Magnesium leading to fewer action potentials being triggered 42. Our figures throughout 
show that, a decrease in the frequency of contractions usually preceded a fall in force. This 
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finding is consistent with observations on human myometrium12,43. Additionally, although 
not yet tested in uterus, Magnesium may affect inter-cellular coupling such as via gap 
junctions 44,45, hence reducing the likelihood of frequent, synchronous contractions being 
produced.  
Gestational effects
In spontaneous contractions, the effect of MgSO4 was most potent at term, and least potent 
in non-pregnant tissues. The latter group were not staged for estrous and should therefore 
be treated as a mean of any cyclical, estrous changes46,47 We found that even on day 16 of 
gestation, Magnesium’s effect on the myometrium was significantly less than at term, 
suggesting that the changes in sensitivity are on-going throughout pregnancy. Given that the 
underlying mechanism of Magnesium’s effects is via decreasing excitability and Calcium entry, 
then our findings point to a difference in the Calcium channels with gestation. There have 
been surprisingly few studies of L-type Calcium expression with gestation in the myometrium.  
The work that has been done suggests an increase in expression and changes of subunits from 
mid-gestation onwards.  Tezuka et al (1995)16 found a marked increase in α1 expression in 
pregnancy, especially in the last half of gestation until term, followed by a decrease during 
labour.  Similarly, Mershon et al (1994)17 studied the expression of α1 subunit and showed a 
gradual increase in the mRNA towards term followed by a decrease during parturition. They 
also showed an increase in the number of dihydropyridine binding sites (markers for L-type 
channels) in the last half of gestation. Thus, a simple effect on Calcium entry is difficult to 
propose to explain gestational differences, unless the switch to increased α-1 subunits 
confers an increased susceptibility to Magnesium blockade.  Rather, our data suggests that at 
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term the effect of Magnesium is sufficientenough to reduce excitability and make action 
potential firing less likely, as occurs with its use in neuronal tissues to protect the brain.  
Oxytocin and Magnesium
To determine if MgSO4 can affect contractile parameters in the presence of an agonist, its 
effect on oxytocin-evoked contractions was determined. Oxytocin was used due to its 
particular importance to labour.  Oxytocin can directly and indirectly stimulate myometrial 
contractions 19. Our data show that a greater concentration of Magnesium is needed to inhibit 
oxytocin-stimulated contractions compared to spontaneous contractions in pregnant tissues.  
This is in agreement with data from other studies including human myometrium 14,33.  
However, oxytocin did not significantly change the IC50 for Magnesium in non-pregnant 
tissues, from that found for spontaneous contractions. We found this to be the case even 
when oxytocin was used at 1nM i.e. double the oxytocin concentration used in pregnant 
tissues. There was no difference in the potency of MgSO4 on oxytocin-stimulated contractions 
between the different gestational groups. The greatest shift in Magnesium's potency with 
oxytocin was observed for term-pregnant myometrium; this shifted the IC50 from around 3 
mM in spontaneous conditions to almost 10 mM.  In terms of clinical applications, the effect 
of oxytocin is to shift the dose from therapeutic to lethal. Therapeutic doses of Magnesium 
are reported at 2.5 mM (5 mEq/L ) or below 12, and for  seizure management in preeclampsia, 
3 mM 33. 
Although oxytocin acts via several mechanisms, an important mechanism is increasing 
membrane potential (resulting in opening of the L-type Ca2+ channels and increased Calcium 
entry), releasing Calcium from the sarcoplasmic reticulum and preventing Calcium exit 19. 
These mechanisms will counteract Magnesium’s actions and may explain why a greater 
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concentration of MgSO4 is needed to inhibit oxytocin induced contractions close to term. The 
lipid environment around the oxytocin receptor  influences its affinity for oxytocin 19,48,49 , an 
effect attributed to its partitioning into lipid rafts and their effect on signal transduction 50,51. 
It was also reported that as well as high cholesterol, the high affinity form of the oxytocin 
receptor requires Magnesium, working as an allosteric modulator. Thus, when Magnesium is 
increased it may increase the oxytocin signalling and further counter the relaxant effect of 
Magnesium on Calcium entry. 
Transition to labour in humans is associated with increased oxytocin receptor expression 52, 
which increases the sensitivity of the uterus towards oxytocin 53. An increase in oxytocin 
receptor expression towards term in mouse, has also been shown 53.  Consistent with this is 
our finding that little, if any, contractility stimulation to 0.5nM oxytocin was observed in non-
pregnant tissues and hence the use of 1nM, to assess the effect of oxytocin on the potency 
of MgSO4 (control data, not shown). Although not accounting for the lack of gestational 
differences, the increased drive on contraction produced by oxytocin, and the increased 
number of receptors, and increased affinity, may also partly explain why a greater 
concentration of MgSO4 is needed to inhibit  contractions in its presence.  In addition, other 
mechanisms operated by Calcium-independent pathways may also be stimulated by oxytocin 
and be affected by elevated Magnesium. However, the role of Ca-sensitisation in uterus is 
thought to be minor 54. This work, and studies by others, has not considered possible effects 
of magnesium on potassium channels.
Conclusion
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This in vitro study shows that MgSO4, acting extracellularly, concentration-dependently 
inhibits spontaneous and oxytocin-induced myometrial contractions in both the pregnant and 
non-pregnant mouse, with greater efficacy observed in term-pregnant tissues. However, 
oxytocin decreases the potency of MgSO4 in pregnant tissues, due to its stimulation of 
contraction and perhaps due to Magnesium allosterically increasing the affinity of the 
oxytocin receptor, which may underlie its lack of efficacy as a relaxant i.e. tocolytic, in vivo.
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Table 1: 
Changes in contractile properties of spontaneous contractions in response MgSO4
Contractile 
properties
Gestational 
States
2mM 
(%±S.E.M)
4mM 
(%±S.E.M)
6mM 
(%±S.E.M)
8mM 
(%±S.E.M)
10mM 
(%±S.E.M)
Non-pregnant 95.8  ± 1.1 * 93.1 ± 1.6 * 90.9 ± 2.3  ** 86.2 ± 3.1 ** 81.5 ± 3.5 **
Mid-term 94.6 ± 1.6 90.6 ± 2.4 83.9 ± 3.1 ** 65.8 ± 11.6 * 57.3 ± 14.9 **Amplitude
Term-pregnant 91.8 ± 2.7 * 61.8 ± 10.9 ** 56.9 ± 11.5 ** 38.3 ± 9.9 ** 19.6 ± 9.8 ***
Non-pregnant 87.9  ± 4.9  * 70.6  ± 5.0 ** 62.7  ± 4.3 ** 45.9 ± 5.7 ** 31.2 ± 2.9 **
Mid-term 84.9 ± 8.7 64.9 ± 7.0 ** 48.9 ± 3.9 ** 32.2 ± 9.01 ** 23.4 ± 8.3 **Frequency
Term-pregnant 72.5 ± 6.7 ** 43.6 ± 8.2 ** 35.5 ± 7.8 *** 20.5 ± 7.1 ** 9.6 ± 5.0 ***
Non-pregnant 83.7  ± 4.4  ** 73.1  ± 4.2  ** 57.7  ± 5.3 ** 48 ± 5.1 *** 40.1 ± 4.5  ***
Mid-term 83.9 ± 4.7 * 63.7 ± 4.2 * 48.0 ± 5.1 ** 26.9 ± 10.5 ** 19.9 ± 9.4 **AUC
Term-pregnant 71.3 ± 6.4 ** 43.3 ± 6.7  *** 33.1 ± 6.5 *** 18.0 ± 5.4 *** 6.1 ± 3.2 ***
Mean data showing concentration-dependent decrease in amplitude, frequency and AUC of 
spontaneously contracting non-pregnant, mid-term (day 14 and 16) and term-pregnant 
myometrium. Values are expresses as Mean ± standard error mean (S.E.M). A significant difference 
in activity was found using ANOVA with Bonferroni post hoc analysis. * denotes a significant 
difference compared to control period (100%) p<0.05, **p<0.01, ***p<0.0001.
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Table 2: 
Changes in contractile properties of oxytocin-induced contractions in response to MgSO4
Contractile 
properties
Gestational 
States
2mM 
(%±S.E.M)
4mM 
(%±S.E.M)
6mM 
(%±S.E.M)
8mM 
(%±S.E.M)
10mM 
(%±S.E.M)
12mM
(%±S.E.M)
20mM
(%±S.E.M)
Non-
pregnant 98.7 ± 0.7  96.7± 1.1 * 95.0 ± 2.1 * 92.7 ± 2.4  *
90.8 ± 2.6  
** 89.3 ± 1.9 * 81.2 ± 5.4*
Mid-term 98.1 ± 1.2 * 90.5 ± 4.8 * 84.2 ± 3.7 ** 81.2 ± 4.8 ** 72.2 ± 8.1**
62.8 ± 5.4 
***
5.9 ± 2.6**Amplitude
Term-
pregnant 98.8 ± 1.0 * 95.5 ± 1.2 ** 90.6 ± 1.7 ** 84.0 ± 2.0 **
71.3 ± 7.4 
***
71.0 ± 4.9 
***
4.4 ± 4.4**
 
Non-
pregnant 85.3 ± 2.7 ** 66.1 ± 4.0 ** 48.0 ± 5.0 ** 40.0 ± 5.6 ** 35.7 ± 5.5 **
36.1 ± 4.1 
*** 47.0 ± 7.9**
Mid-term 92.8 ± 3.1 * 90.4 ± 4.1 *
79.9 ± 11.8 
**
75.4 ± 11.9 
**
67.5 ± 10.5 
**
58.0 ± 13.2 
** 2.5 ± 0.1Frequency
Term-
pregnant 93.9 ± 2.3 88.3 ± 3.2 ** 77.2 ± 3.2 **
65.7 ± 
3.4***
57.9 ± 3.3 
***
58.0 ± 3.9 
*** 1.8 ± 1.8***
 
Non-
pregnant 88.7 ± 2.6 ** 73.4 ± 4.9 ** 58.0 ± 6.1 ** 54.2 ± 5.0 **
44.8 ± 5.21 
** 38.9 ± 0.9 ** 38.8 ± 5.8**
Mid-term 94.7 ± 2.5 * 90.0 ± 3.3 *
67.1 ± 11.0 
**
65.6 ± 4.5 
*** 48.8 ± 9.3 ** 34.9 ± 8.8** 2.1 ± 0.9***AUC
Term-
pregnant 93.8 ± 1.2 83.3 ± 1.5 ** 73.6 ± 2.6 ** 60.9 ± 3.5 ** 50.5 ± 3.9 ** 41.3 ± 6.7 ** 1.7 ± 1.7***
Mean data showing concentration-dependent decrease in amplitude, frequency and AUC of 
oxytocin-induced contracting non-pregnant, mid-term (day 14 and 16) and term-pregnant 
myometrium. Values are expressed as Mean ± standard error mean (S.E.M). Significant difference in 
activity was found using ANOVA with Bonferroni post hoc analysis. * denotes a significant difference 
compared to control period (100%) p<0.05, **p<0.01, ***p<0.0001.
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Figure legends
Figure 1:  The effects of Magnesium on contractions of mouse myometrium.
Typical records showing contractions obtained from term-pregnant mouse myometrium. In 
this and all subsequent figures, data were obtained at 37°C and pH 7.4, with tissues 
superfused with physiological saline (containing 1. 2 mM MgSO4), in the absence (A & 
B)  and presence of increased  (10 or 20 mM) Magnesium as sulfate (C ) or  chloride (D) salt. 
Traces B, C & D, were in the presence of oxytocin (0.5 nM).
Figure 2:  The effects of Magnesium sulfate on spontaneous contractions of mouse 
myometrium.
Representative isometric traces showing the effect of increasing concentrations of 
Magnesium sulfate in (A) non-pregnant, (B) 14-day pregnant, (C), 16-day pregnant and (D) 
term-pregnant myometrium. The coloured bars indicate the 15-minute period when 
Magnesium sulfate was added. In all gestational states, a reduction in amplitude and 
frequency was observed with increased concentration.  (E ) The concentration-response 
curves showing the effect of Magnesium sulfate on force area under the curve (AUC) at 
different gestational states (non-pregnant :  green circle, 14-day: blue square, 16-day: red 
diamond, term pregnant: purple triangle). The concentration-response curves significantly 
shifted to the left as gestation increased (P<.0001). Significant difference was found using 
ANOVA with Bonferroni post hoc test.
Figure 3:  The effects of Magnesium sulfate on oxytocin-induced contractions of mouse 
myometrium.
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Representative isometric traces showing the effect of increasing concentrations of 
Magnesium in (A), non-pregnant myometrium, (B), 14-day pregnant, (C), 16-day pregnant 
and (D), term-pregnant myometrium in the presence of oxytocin (1 nM used for non-
pregnant tissue and 0.5 nM for all pregnant tissues). The short, coloured bars indicate the 
15-minute period where Magnesium sulfate was added. Increasing concentration of 
Magnesium sulfate (2-12mM) caused gradual reduction in amplitude and frequency of 
contractions in all gestational states. (E) The concentration-response curves show the effect 
of Magnesium sulfate on AUC of contraction at different gestational states (non-pregnant:  
green circle, 14-day: blue square, 16-day: red diamond, term-pregnant: purple triangle). 
There was no significant difference between the concentration-response curves for the 
different gestational states, determined using ANOVA with Bonferroni post hoc test. 
Figure 4:  The effect of Magnesium sulfate between spontaneous and oxytocin-induced 
contractions at different gestational states.
The concentration-response curves show the effect of Magnesium sulfate on force integral 
(AUC) of contraction in spontaneous (green circles) and oxytocin-induced contractions 
(purple squares). There was no significant difference (P=0.062) between the concentration-
response curves of non-pregnant myometrium (A). For 14-day (B), 16-day (C) and term-
pregnant myometrium (D), the concentration-response curves were significantly shifted to 
the right in the presence of oxytocin, indicating a significantly greater concentration of 
Magnesium is required to reduce contractions in the presence of oxytocin compared to 
spontaneous contractions (P<.0001, P<0.01 and P<0.0001 respectively). Significant 
difference in activity was determined using the extra sum of squares F-test.
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Figure 1: The effects of magnesium on
contractions of mouse myometrium.
Typical records showing contractions obtained
from term-pregnant mouse myometrium. In this
and all subsequent figures, data were obtained at
37°C and pH 7.4, with tissues superfused with
physiological saline (containing 1. 2 mM MgSO4),
in the absence (A & B) and presence of increased 
(10 or 20 mM) magnesium as sulfate (C ) or
chloride (D) salt. Traces B, C & D, were in the
presence of oxytocin (0.5 nM).
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Magnesium on spontaneous contractions
Figure 2: The effects of magnesium sulfate on 
spontaneous contractions of mouse myometrium.
Representative isometric traces showing  the effect of increasing 
concentrations of magnesium sulfate in (A) non-pregnant, (B) 14-
day pregnant, (C), 16-day pregnant and (D) term-pregnant 
myometrium. The coloured bars indicate the 15-minute period 
when magnesium sulfate was added. In all gestational states, a 
reduction in amplitude and frequency was observed with 
increased concentration.  (E )The concentration-response curves 
showing the effect of magnesium sulfate on force area under the 
curve (AUC) at different gestational states (non-pregnant :  green 
circle, 14-day: blue square, 16-day: red diamond, term pregnant: 
purple triangle). The concentration-response curves significantly 
shifted to the left as gestation increased (P<.0001). Significant 
difference was found using ANOVA with Bonferroni post hoc test.
10- 4 10- 3 10- 2 10- 1 100
0
60
120 Non-pregnant
14-day
16-day
18-day
Spontaneous contractions
Log [MgSO4] (M)
%
 c
o
n
tr
o
l 
A
U
C
***
E
Term-
pregnant 
Non-
pregnant 
14-day 
pregnant 
16-day 
pregnant
2 4 1086
12
0
Force
(mN)
A Mg mM
8
0
Force
(mN)
B
10
0
Force
(mN)
C
14
0
Force
(mN)
D
Page 29 of 31
http://mc.manuscriptcentral.com/rsci
Reproductive Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Non-
pregnant 
14-day 
pregnant 
Term-
pregnant 
Magnesium on Oxytocin-induced contractions
16-day 
pregnant 
Figure 3: The effects of magnesium sulfate on 
oxytocin-induced contractions of mouse 
myometrium.
Representative isometric traces showing the effect of increasing 
concentrations of magnesium in (A), non-pregnant myometrium, (B), 
14-day pregnant, (C), 16-day pregnant and (D), term-pregnant 
myometrium in the presence of oxytocin (1 nM used for non-
pregnant tissue and 0.5 nM for all pregnant tissues).The short, 
coloured bars indicate the 15-minute period where magnesium 
sulfate was added. Increasing concentration of magnesium sulfate 
(2-12mM) caused  gradual reduction in amplitude and frequency of 
contractions in all gestational states. (E) The concentration-response 
curves show the effect of magnesium sulfate on AUC of contraction 
at different gestational states (non-pregnant :  green circle, 14-day: 
blue square, 16-day: red diamond, term-pregnant: purple triangle). 
There was no significant difference between the concentration-
response curves for the different gestational states, determined 
using ANOVA with Bonferroni post hoc test. 
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Figure 4:  The effect of magnesium sulfate between spontaneous and oxytocin-induced contractions at different 
gestational states.
The concentration-response curves show the effect of magnesium sulfate on force integral (AUC) of contraction in spontaneous  (green 
circles) and oxytocin-induced contractions (purple squares). There was no significant difference (P=0.062) between the concentration-
response curves of non-pregnant myometrium (A). For 14-day (B), 16-day (C) and term-pregnant myometrium (D), the concentration-
response curves were significantly shifted to the right in the presence of oxytocin, indicating a significantly greater concentration of Mg is 
required to reduce contractions in the presence of oxytocin compared to spontaneous contractions (** indicates P<0.01, ***P<0.0001). 
Significant difference in activity was determined using the extra sum of squares F-test.
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